Medicine and Dentistry
Patient
100%
Treprostinil
78%
Pulmonary Hypertension
42%
Connective Tissue Disease
28%
Subcutaneous Injection
21%
Dyspnea
14%
Symptom
14%
Fatigue
14%
Prostacyclin Derivative
14%
Measurement
7%
Side Effect
7%
New York Heart Association Class
7%
Exercise
7%
Adverse Event
7%
Infusion
7%
Lung Vascular Resistance
7%
Systemic Lupus Erythematosus
7%
Mixed Connective Tissue Disease
7%
Prostaglandin
7%
Diffuse Scleroderma
7%
Pain
7%
Resistance Index
7%
Overlap Syndrome
7%
Limited Scleroderma
7%
Amaurosis
7%
Nursing and Health Professions
Treprostinil
78%
Placebo
50%
Pulmonary Hypertension
42%
Connective Tissue Disease
28%
Inpatient
28%
Dyspnea
14%
Fatigue
14%
Symptom
14%
Dose
14%
Prostacyclin Derivative
14%
Measurement
7%
Adverse Event
7%
Lung Vascular Resistance
7%
Side Effect
7%
New York Heart Association Class
7%
Pain
7%
Infusion
7%
Systemic Lupus Erythematosus
7%
Prostaglandin
7%
Cardiac Index
7%
Maximum Permissible Dose
7%
Diffuse Scleroderma
7%
Blindness
7%
Limited Scleroderma
7%
Mixed Connective Tissue Disease
7%
INIS
patients
64%
hypertension
42%
diseases
35%
connective tissue
35%
infusion
28%
distance
21%
doses
21%
range
14%
symptoms
14%
fatigue
14%
capacity
7%
design
7%
comparative evaluations
7%
interventions
7%
safety
7%
new york
7%
pain
7%
side effects
7%
exercise
7%
lupus
7%
prostaglandins
7%